Recommendation of the President – Kisqali (ribociclib)
On 21 May 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 65/2025 on the appraisal of drug Kisqali (ribociclib) under the B.9.FM drug program “Treatment of patients with breast cancer (ICD-10: C50)” deep cleaning